Composition of common bile duct stones in Chinese patients during and after endoscopic sphincterotomy

Wei-Lun Tsai, Kwok-Hung Lai, Chiun-Ku Lin, Hoi-Hung Chan, Ching-Chu Lo, Ping-I Hsu, Wen-Chi Chen, Jin-Shiung Cheng, Gin-Ho Lo

AIM: Endoscopic sphincterotomy (ES) is a well-established therapeutic modality for the removal of common bile duct (CBD) stones. After ES there are still around 10% of patients that experience recurrent CBD stones. The aim of this study is to investigate the composition of CBD stones before and after ES and its clinical significance in Chinese patients.

METHODS: From January 1996 to December 2003, 735 patients with CBD stones received ES at Kaohsiung Veterans General Hospital and stone specimens from 266 patients were sent for analysis. Seventy-five patients had initial CBD stones and stone specimens from 44 recurrent CBD stones were obtained. The composition of initial or recurrent CBD stone in Chinese patients was analyzed by infrared (IR) spectrometry and they were classified as cholesterol or bilirubinate stones according to the predominant composition. Clinical data were analyzed.

RESULTS: In the initial 266 stone samples, 217 (82%) were bilirubinate stones, 42 (16%) were cholesterol stones, 3 were calcium carbonate stones, 4 were mixed cholesterol and bilirubinate stones. Patients with bilirubinate stones were significantly older than patients with cholesterol stones (66±13 years vs 56±17 years, P = 0.001). In the 44 recurrent stone samples, 38 (86%) were bilirubinate stones, 3 (7%) were cholesterol stones, and 3 were mixed cholesterol and bilirubinate stones. In 27 patients, both initial and recurrent stone specimens can be obtained, 23 patients had bilirubinate stones initially and 2 became cholesterol stones in the recurrent attack. In the four patients with initial cholesterol stones, three patients had bilirubinate stones and one patient had a cholesterol stone in the recurrent attack.

CONCLUSION: Bilirubinate stone is the predominant composition of initial or recurrent CBD stone in Chinese patients. The composition of CBD stones may be different from initial stones after ES.

Key words: Endoscopic sphincterotomy; Common bile duct stone; Bilirubinate stone; Cholesterol stone

Tsai WL, Lai KH, Lin CK, Chan HH, Lo CC, Hsu PI, Chen WC, Cheng JS, Lo GH. Composition of common bile duct stones in Chinese patients during and after endoscopic sphincterotomy. World J Gastroenterol 2005; 11(27): 4246-4249

INTRODUCTION
The prevalence of gallstone diseases varied from 10% to 30% in the normal population and increased with age[4-6]. Most gallstones are asymptomatic, but symptomatic gallstones may occur due to either cystic duct obstruction or common bile duct (CBD) stone formation. Endoscopic sphincterotomy (ES) is a well-established therapeutic modality for the removal of CBD stones. In follow-up studies after ES, 3-21% of patients developed recurrent CBD stones[4-6] and most of them can be treated successfully by endoscopy[4-7].

The main composition of gallstones is cholesterol and bile pigments[8]. The major composition of GB stones obtained from Western patients is cholesterol (consisting of more than 50% cholesterol)[8]. However, in the Asian patients, most gallstones are pigmented stones[9]. Pigmented stones can be classified as black stones, associated with hemolysis or brown stones, associated with infection or bile stasis[10-13]. Stones in the CBD are often brown, pigmented stones[8-10]. After ablation of sphincter, bactobilia may happen and the pathogenesis of CBD stone formation may be different from the patients with intact sphincter[17,18]. There have been few studies reporting the composition of recurrent CBD stones in patients after ES.

The aim of this study is to determine the composition of initial and recurrent CBD stones by infrared (IR) spectrometry and investigate the relationship of clinical characteristics and the change of the composition of recurrent stones after ES.

MATERIALS AND METHODS
Since January 1996 to December 2003, total 735 patients
with CBD stones received successful ES with clearance of CBD stones in Kaohsiung Veterans General Hospital and 266 stone specimens were collected and sent for stone analysis. During clinical follow-up, 75 patients had recurrent stones and 44 stone specimens were collected for stone analysis. Clinical data such as age, sex, diameter of CBD, size, number and color of stones, presence of juxtapapillary diverticulum (JPD), gallbladder (GB) status, and GB stones were recorded. GB stone was detected by sonogram or computed tomography of abdomen. Diameter of CBD and size and number of stones were measured during endoscopic retrograde cholangiopancreatography.

The stone sample was retrieved by Dormia basket (FG-22Q-1, Olympus) or snarenet (Roth snarenet, U.S.E.) from the bile duct. The stone specimen was pulverized into a homogenous powder, mixed with KBr and ground into fine particles. The mixed powder was pressed with a hydraulic pressure of 400 psi for 1 min to form a disc. Sample disc was analyzed with IR spectrometer. The stones were classified as cholesterol or bilirubinate stone according to the predominant composition. The characteristic band features and key band locations were in accordance with those reported in the literature.[9,19] Bilirubinate stones had characteristic IR absorption bands at 970, 1 186, 1 250, 1 568, 1 627, and 1 650/cm with a key band at 1 250/cm; characteristic IR absorption bands at 970, 1 186, 1 250, 1 050, and 1 470/cm were recorded with CBD stones.

In the 75 patients with stone collection, their CBD diameter, size and number of CBD stones, GB status, and presence of gallstones between patients with recurrent bilirubinate or cholesterol stones (Table 2).

### Table 1 Patients’ characteristics between stone collected and un-collected groups

| Age (yr) | Collected (n = 266) | Uncollected (n = 469) | P   |
|----------|---------------------|-----------------------|-----|
| Age (yr) | 64±14               | 65±14                 | 0.454 |
| Sex (M/F)| 156/110             | 297/172               | 0.210 |
| JPD (%)  | 105 (39)            | 158 (34)              | 0.116 |
| Cholecystectomy (%) | 65 (24) | 108 (23) | 0.665 |
| CBD size (cm) | 1.7±0.6 | 1.5±0.6 | <0.001 |
| CBD-stone size (cm) | 1.2±0.6 | 0.6±0.7 | <0.001 |

| Stone number (S/M) | 111/106 | 16/26 | 0.410 |
| Stone size (cm) | 1.2±0.6 | 1.2±0.7 | 0.012 |
| CBD diameter (cm) | 1.9±0.6 | 1.4±0.2 | 0.159 |
| CBD size (cm) | 1.2±0.6 | 1.2±0.7 | 0.012 |
| CBD diameter (cm) | 1.9±0.6 | 1.4±0.2 | 0.159 |
| CBD size (cm) | 1.2±0.6 | 1.2±0.7 | 0.012 |
| CBD diameter (cm) | 1.9±0.6 | 1.4±0.2 | 0.159 |
| CBD size (cm) | 1.2±0.6 | 1.2±0.7 | 0.012 |

### Table 2 Patients’ characteristics and initial stone compositions

| Age (yr) | Bilirubinate (n = 217) | Cholesterol (n = 42) | P   |
|----------|------------------------|----------------------|-----|
| Age (yr) | 66±13                  | 56±17                | 0.001 |
| Sex (M/F) | 130/87               | 22/20                | 0.365 |
| CBD diameter (cm) | 1.7±0.5 | 1.6±0.6 | 0.119 |
| Stone size (cm) | 1.2±0.6 | 1.2±0.7 | 0.410 |
| Stone number (S/M) | 111/106 | 16/26 | 0.121 |
| JPD      | Present               | Absent               | 0.084 |
| Present  | 93 (43)               | 12 (29)              | 0.323 |
| Absent   | 124 (57)              | 30 (71)              | 0.210 |
| Cholecystectomy | 57 (26) | 8 (19) | 0.121 |
| Cholecystectomy | 57 (26) | 8 (19) | 0.121 |

### Table 3 Patients’ characteristics and compositions of recurrent CBD stones

| Age (yr) | Bilirubinate (n = 38) | Cholesterol (n = 3) | P   |
|----------|-----------------------|---------------------|-----|
| Age (yr) | 66±10                 | 65±6                | 0.826 |
| Sex (M/F) | 21/17                | 3/0                 | 0.254 |
| CBD diameter (cm) | 1.9±0.6 | 1.4±0.2 | 0.159 |
| Stone number (S/M) | 16/22 | 1/2 | 1.000 |
| Stone size (cm) | 1.4±0.8 | 0.8±0.4 | 0.096 |
| JPD      | Present               | Absent               | 0.543 |
| Present  | 13 (34)               | 2 (67)               | 0.001 |
| Absent   | 25 (66)               | 1 (33)               | 0.001 |
| Cholecystectomy | 18 (47) | 1 (33) | 0.001 |
| Cholecystectomy | 18 (47) | 1 (33) | 0.001 |

A total 75 patients had recurrent CBD stones and received another endoscopic treatment. Stone specimens were collected from 44 patients for stone analysis. In the 44 recurrent stone samples, 38 (86%) were bilirubinate stones, 5 (7%) were cholesterol stones, and 3 were mixed cholesterol and bilirubinate stones. Among the three patients with recurrent cholesterol stones, two patients had intact GBs with stones and one had received a cholecystectomy 6 mo prior to recurrence. There were no significant differences in age, sex, CBD diameter, size or number of CBD stones, GB status, or presence of gallstones between patients with recurrent bilirubinate or cholesterol stones (Table 3).
In 27 patients, both initial and recurrent stone specimens can be obtained and sent for analysis, 23 patients had bilirubinate stones at initial treatment, 21 of them still had bilirubinate stones and 2 patients had cholesterol stones after recurrence. Both the patients with recurrent cholesterol stones also had GB stones. Four patients had cholesterol stones in the initial attack, three of them had bilirubinate stones, one patient still had cholesterol stones with recurrence and this patient had received cholecystectomy 6 mo prior to recurrence (Table 4).

### Table 4 Change of stone compositions between initial and recurrent stone

|          | Initial          | Recurrent          |
|----------|------------------|--------------------|
|          | Bilirubinate     | Cholesterol        |
| n = 23   | n = 24           | n = 4              |
| Bilirubinate | 21               | 3                  |
| Cholesterol | 2               | 1                  |

Among the initial 266 stone samples, colors of stones were recorded. In the 217 patients with bilirubinate stones, 55 were yellowish, 93 were blackish, 64 were brownish and 5 were greenish. In the 42 patients with cholesterol stones, 15 were yellowish, 12 were blackish, 15 were brownish. In patients with mixed bilirubinate and cholesterol stones, two were yellowish and two were blackish. In patients with calcium carbonate stones, two were yellowish and one was blackish (Table 5).

### Table 5 Compositions and color of stones

|                  | Bilirubinate stone (n = 217) | Cholesterol stone (n = 42) | Mixed bilirubinate and cholesterol stone (n = 4) | Calcium carbonate stone (n = 3) |
|------------------|-------------------------------|---------------------------|-----------------------------------------------|---------------------------------|
| Yellow           | 55                            | 15                        | 2                                             | 2                              |
| Black            | 93                            | 12                        | 2                                             | 1                              |
| Brown            | 64                            | 15                        | 0                                             | 0                              |
| Green            | 5                             | 0                         | 0                                             | 0                              |

**Discussion**

We found that 82% of our patients had bilirubinate stones in the first attack, so the mechanism of CBD stone formation is different from the Western countries, but it is similar to some Asian studies. After ablation of sphincter of Oddi by ES, bactobilia may happen from direct extension of duodenal organisms into the CBD and β-glucuronidase released by the bacteria can promote the formation of bilirubinate stones. This explains why bilirubinate stone is the predominant composition of recurrent CBD stones (86%) after ES. Unlike the cholesterol stones, bilirubinate stones are often soft and easily broken, so complete clearance of bilirubinate stones even after ES may be inadequate; some radiologically undetectable small fragments of bilirubinate stones may be left in the CBD; in addition to impaired biliary emptying, it may lead to bilirubinate stone formation at a later time.

Among the initial 42 patients with cholesterol stones, 8 patients received cholecystectomy at least 3 mo (median: 60 mo, range: 3-120 mo) before ES and 14 patients had intact GB but no GB stones. Besides spontaneous pass-out of stones, de novo formation of cholesterol stones from CBD may also be possible in these patients.

In previous reports, JPD may facilitate primary CBD stone, but not GB stones formation. In our study, patients with initial bilirubinate stones had higher incidence of JPD than patients with initial cholesterol stones (43% vs 29%), but the difference did not reach statistical significance (P = 0.084).

In the 23 patients with initial bilirubinate stones, 21 had bilirubinate stones at recurrence, 2 had cholesterol stones when recurrence and these 2 patients also had GB stones at the time of recurrence, so stone pass-out from the GB may possibly explain the cholesterol composition of their CBD stones. In the four patients with initial cholesterol stones, three patients had bilirubinate stones and one had cholesterol stones at recurrence. The patient, who had recurrent cholesterol stones, had received cholecystectomy 6 mo before. It is difficult to determine whether the cholesterol stone is formed in the bile duct or GB. Our results indicated that different mechanism of CBD stone formation might occur in the same patient after ablation of sphincter leading to the formation of a different composition of stones.

In this study, we found that patients with bilirubinate stones are older than patients with cholesterol stones. Similar data have been found in Western patients with cholesterol pigment GB stones. It is well known that the duodenum is usually sterile in young healthy patients, but immunological and motor function of the alimentary tract may deteriorate gradually with age. The bacterial colonization of the CBD is an age-dependent phenomenon and this may explain the higher incidence of bilirubinate stones in older patients.

Cholesterol stones were usually yellowish or brownish, but 12 out of 42 (29%) cholesterol stones in our patients were black in color, whereas 93 out of 217 (43%) bilirubinate stones were black in color. The nature of CBD stones cannot be completely determined by gross appearance alone and the IR spectroscopy is an important tool to determine the exact composition of stones.

For most patients, endoscopic retrieval of stones for analysis is more difficult than surgical procedure. In our study, only 266 out of 735 patients had received the analysis of stones. It could be speculated that different stone composition may influence the collection of stone for analysis during extraction procedure. Cholesterol stones are often smoother and harder while bilirubinate stones, on the other hand, are softer and tend to be broken down into small fragments when retrieved by basket or even a snarenet. This infers that the real percentage of bilirubinate stones in our patients may be actually higher. However, our analysis does not show significant difference in age, sex, presence of JPD, or cholecystectomy between patients whose stones were collected for analysis or not. Even though the CBD diameter and stone size are larger in the patients with stone analysis, there is no difference in CBD size or stone size between bilirubinate or cholesterol stones. We believe that little selection bias has taken place in our patients, despite only about 36% of patients’ stones were collected for analysis.
In conclusion, bilirubinate stones are the predominant composition of initial and recurrent CBD stone after ES in Chinese patients. Patients with bilirubinate stones are older than those with cholesterol stones. The composition of stones may change after ES.

ACKNOWLEDGMENTS

The authors thank Mr. E-Ming Wang, Miss. Min-Ching Wei, and Ming-Ti Fu for their assistance in follow-up visits and data management and Dr. Ying-Huei Lee for stone analysis.

REFERENCES

1. Bates T, Harrison M, Lawson C, Padley N. Longitudinal study of gall stone prevalence at necropsy. Gut 1992; 33: 103-107
2. Heaton KW, Braddon FM, Mountford RA, Hughes AO, Emmett PM. Symptomatic and silent gall stones in the community. Gut 1991; 32: 316-320
3. Su CH, Lui WY, P’eng FK. Relative prevalence of gallstone diseases in Taiwan: A nationwide cooperative study. Dig Dis Sci 1992; 37: 764-768
4. Lai KH, Peng NJ, Lo GH, Cheng JS, Huang RL, Lin CK, Huang JS, Chiang HT, Ger LP. Prediction of recurrent choledocholithiasis by quantitative chlroscintigraphy in patients after endoscopic sphincterotomy. Gut 1997; 41: 399-403
5. Hawes RH, Cotton PB, Vallon AG. Follow-up 6-11 years after duodenoscopic sphincterotomy for stones in patients with prior cholecystectomy. Gastroenterology 1990; 98: 1008-1012
6. Seifert E. Long-term follow-up after endoscopic sphincterotomy (EST). Endoscopy 1988; 20: 232-235
7. Lai KH, Lo GH, Lin CK, Hsu PI, Chan HH, Cheng JS, Wang EM. Do patients with recurrent choledocholithiasis after endoscopic sphincterotomy benefit from regular follow-up. Gastrointest Endosc 2002; 55: 523-526
8. Carey MC. Pathogenesis of gallstones. Am J Surg 1993; 165: 410-419
9. Huang SM, Su CH, Wu LH, Chang TJ, Wu CW, Lee CH, Lui WY. Polarising microscopy versus infrared absorption spectroscopy in gallstone analysis- a preliminary report. Asian J Surg 1988; 12: 172-177
10. Cahalane MJ, Neubrand MW, Carey MC. Physical-chemical pathogenesis of pigment gallstones. Semin Liver Dis 1988; 8: 317-328
11. Crowther RS, Soloway RD. Pigment gallstone pathogenesis: from man to molecules. Semin Liver Dis 1990; 10: 171-180
12. Trotman BW. Pigments gallstone disease. Gastroenterol Clin N Am 1991; 20: 111-126
13. Leuschner U, Guldutuna S, Hellstern A. Pathogenesis of pigment stones and medical treatment. J Gastroenterol Hepatol 1994; 9: 87-98
14. Malet PF, Dabezies MA, Huang G, Long WB, Gadacz TR, Soloway RD. Quantitative infrared spectroscopy of common bile duct gallstones. Gastroenterology 1988; 94: 1217-1221
15. Bernhoff RA, Pellegrini CA, Motson RW, Way LW. Composition and morphologic and clinical features of common duct stones. Am J Surg 1984; 148: 77-85
16. Sandsted O, Osnes T, Skar V, Urdal P, Osnes M. Common bile duct stones are mainly brown and associated with duodenal diverticula. Gut 1994; 35: 1464-1467
17. Gregg JA, Girolami PD, Carr-Locke DL. Effects of sphincteroplasty and endoscopic sphincterotomy on the bacteriologic characteristics of the common bile duct. Am J Surg 1985; 149: 668-671
18. Skar V, Skar AG, Midtvedt T, Osnes M. Bacterial growth in the duodenum and in the bile of patients with gallstone disease treated with endoscopic papillotomy (EPT). Endoscopy 1986; 18: 10-13
19. Lee YH, Chen MT, Huang JK, Chang LS. Analysis of urinary calculi by infrared spectroscopy. Clin Med J 1990; 45: 157-165
20. Tanaka M, Takahata S, Konomi H, Matsunaga H, Yokohata K, Takeda T, Utsunomiya N, Ikeda S. Long-term consequence of endoscopic sphincterotomy for bile duct stones. Gastrointest Endosc 1998; 48: 465-469
21. Kim DI, Kim MH, Lee SK, Seo DW, Chol WB, Lee SS, Park SJ, Joo YH, Yoo KS, Kim HJ. Risk factors for recurrence of primary bile duct stones after endoscopic biliary sphincterotomy. Gastrointest Endosc 2001; 54: 42-48
22. Cetia F. Do surgical and endoscopic sphincterotomy prevent or facilitate recurrent common duct stone formation? Arch Surg 1993; 128: 329-336
23. Cetia F. The possible role of sphincteroplasty and surgical sphincterotomy in the pathogenesis of recurrent common duct brown stones. HPB Surg 1993; 4: 261-270
24. Ho KJ, Lin XZ, Yu SC, Chen JS, Wu CZ. Cholelithiasis in Taiwan: Gallstone characteristics, surgical incidence, bile lipid composition and role of B-glucuronidase. Dig Dis Sci 1995; 40: 1963-1973
25. Lotveit T. The composition of biliary calculi in patients with juxtapapillary duodenal diverticula. Scand J Gastroenterol 1982; 17: 653-656
26. Trotman BW, Ostrow JD, Soloway RD. Pigment vs cholesterol cholelithiasis: comparison of stone and bile composition. Am J Dig Dis 1974; 19: 585-590
27. Cetia F. The route of infection in patients with bactibilia. World J Surg 1983; 7: 562
28. Wei TC. Quantitative determination of chemical composition of gallstones by infrared absorption spectrophotometry. J Formos Med Assoc 1982; 81: 145-157
29. Chen YJ, Liu MH, Chen PH, Lo HW, Wang CS, Yuan J, Wen KL. Composition analysis of gallstones by fourier transformed infrared spectroscopy. Chin J Gastroenterol 1992; 9: 1-8

Science Editor Guo SY  Language Editor Elsevier HK